COUNTERPATH PATENT PORTFOLIO RECOGNIZED FOR TECHNOLOGY LEADERSHIP
COUNTERPATH PATENT PORTFOLIO RECOGNIZED FOR TECHNOLOGY LEADERSHIP
CounterPath Named “Best & Brightest” by MDB Capital Group VANCOUVER, Feb. 22 /PRNewswire/ – CounterPath Corporation (TSX-V: CCV; OTCBB: CPAH) announced today that it has been named as one of MDB Capital Group’s “Best & Brightest” for 2011 , an annual list of companies who ranked above the 90(th) percentile for technology leadership from more than 1,500 small cap companies with U.S. patents …
Silence Therapeutics Issued New U.S. Patent Covering Fundamental RNA Interference Technology Currently in Several …
LONDON, Feb. 23, 2011 /PRNewswire/ — Silence Therapeutics plc (AIM: SLN) (“Silence” or the “Company”) announces the issuance of United States patent 7,893,245, titled “Interfering RNA Molecules,” by the United States Patent and Trademark Office (USPTO). The issued patent, which represents a continuation of previously issued U.S. Patent Number 7,452,987, covers chemically modified RNAi molecules …
Genentech, Celltech colluded on patent – lawsuit
* Lawsuit says Genentech colluded to get Cabilly patent * Genentech plans to use patent to fight Benlysta – Genome * Complaint seeks damages to Human Genome Sciences WILMINGTON, Del., Feb 23 (Reuters) …
Abbott wins J&J patent case on appeal
BOSTON (MarketWatch) — The U.S. Court of Appeals ruled Wednesday that Abbott Laboratories’ rheumatoid arthritis drug Humira does not infringe upon a key patent for Johnson & Johnson’s Remicade, essentially reversing a 2009 lower court decision that awarded $1.67 billion in damages to J&J. The patent in question is held by J&J and New York University, who jointly brought the suit. “We are very …
Cloud Computing: Prepare for Patent Trolls Now
Avoid getting caught for knowingly or unknowingly infringing on patents.
Patent Office Struggles to Catch Up With Technology
Only in the last three years has the federal Patent and Trademark Office begun to accept a majority of its applications in digital form.